STAT+: Taking stock of the frenzied push into autoimmune disease
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
Good morning! This is a magical time of the year in Boston, with trees in full bloom. I want to hear from you! Send me email at BiotechScorecard@statnews.
Where art thou, lupus patients?
This week, Cullinan Oncology, now known as Cullinan Therapeutics, became the latest company to pivot from cancer to autoimmune disease. It joins Crispr Therapeutics, Cabaletta Bio, Nkarta, Caribou Biosciences, Allogene Therapeutics, Gracell (AstraZeneca), Bristol Myers Squibb, Fate Therapeutics, Eliem Therapeutics/Tenet Medicines, and Century Therapeutics/Clade Therapeutics in making the same shift, either partially or completely.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Taking stock of the frenzied push into autoimmune disease »
